Economy

Trump backs down from 250% EU pharma tariff in deal

Trump scraps 250% EU pharma tariff in settlement

The escalating trade tensions between Washington and Brussels took a significant turn as former U.S. President Donald Trump agreed to withdraw plans for imposing an extraordinarily high tariff—reportedly 250 percent—on pharmaceutical imports from the European Union. This decision, which came as part of a broader trade arrangement, marks a critical moment in the long-standing negotiations between the two economic powerhouses and offers a temporary reprieve for industries on both sides of the Atlantic.The dispute traces back to a period of intensifying trade frictions, during which Washington sought to correct what it viewed as persistent imbalances and unfair practices in sectors…
Read More
Beijing opposes 'bully' US for 50% tariffs on India

Beijing opposes ‘bully’ US for 50% tariffs on India

El panorama del comercio mundial ha entrado en otra fase turbulenta, mientras que Beijing ha criticado con dureza la reciente decisión de Washington de imponer altos aranceles a los productos que provienen de India. Esta medida, que establece un arancel del 50 por ciento sobre una variedad de exportaciones indias hacia los Estados Unidos, ha generado un amplio debate sobre el proteccionismo, la estrategia económica y el futuro de las relaciones comerciales internacionales.China’s condemnation of the policy came swiftly, framing the decision as an example of what it terms “bullying tactics” within the global economic system. According to Chinese officials,…
Read More
Trump backs down from 250% EU pharma tariff in deal

Trump steps away from 250% EU pharma tariff in deal

The possibility of a trade war between the United States and the European Union has been averted after former U.S. President Donald Trump agreed to drop plans for a massive tariff on European pharmaceutical imports. Initially, the Trump administration had signaled the introduction of a 250% tariff on drugs coming from Europe, a move that alarmed both industry leaders and healthcare organizations worldwide. However, following weeks of tense negotiations, both sides have announced a deal aimed at maintaining stability in the global pharmaceutical market.The proposed tariff emerged as part of a broader strategy designed to protect American manufacturing and reduce…
Read More
WH Smith shares tumble 42% after accounting blunder

WH Smith experiences 42% share plunge after accounting blunder

Actions at WH Smith plummeted after revealing a major accounting error that has shaken investors and brought attention to the firm's internal management systems. The retail company, widely recognized for its locations in airports, train stations, and city centers throughout the United Kingdom and abroad, experienced a significant decrease in its market capitalization after acknowledging a financial mistake that exaggerated stated profits.The announcement sent shockwaves through the investment community, with WH Smith’s stock price plummeting by more than 40% in early trading. Analysts described the situation as one of the most severe financial reporting issues the company has faced in…
Read More
Target appoints new boss as it seeks to revive sales

Target appoints new chief executive in bid to revive sales

Target Corporation has revealed a major executive shift, selecting a new CEO as it seeks to boost sales and reshape its standing in the competitive retail sector. This decision arises in response to increasing pressure from shareholders and industry experts who have observed stagnant growth and evolving consumer trends in recent times. The choice underscores Target's dedication to strategic revitalization and enduring stability.The major retailer is navigating a difficult landscape where rapidly changing consumer demands are evident. The rise of online purchases, services prioritizing convenience, and shoppers who are sensitive to prices have pushed conventional retailers to rethink their strategies.…
Read More